Xuanzhu Biopharm set for spin-off in Hong Kong IPO The cash-strapped company has launched a drug to treat duodenal ulcers and is seeking approval for other products, but is up against a host of competing medicines Key Takeaways: Xuanzhu… December 5, 2024 0460.HK